Astrana Health vs Encompass Health
Add, change or remove companies; up to four.
KIRA’s take AI analyst
I put Astrana Health and Encompass Health side by side, using each one’s latest annual report. Here is what stands out:
- Encompass Health is the larger business, with $5.9B of revenue in fiscal 2025 against $3.2B for Astrana Health, about 1.9 times as much.
- Astrana Health grew revenue faster (56.4%, against 10.5%).
- Encompass Health turned more of its sales into free cash flow (7.4% FCF margin, against 3.3%).
- Encompass Health earned a higher return on the capital invested in it (15.8%, against 4.2%).
- Investors pay more for each dollar of Astrana Health’s earnings: a P/E of 44.9x against 20.2x for Encompass Health.
Who comes out ahead
Of the 9 measures where higher (or lower) is clearly better, how many each company leads.
Astrana Health
ASTH
2/9
Revenue growth5-year growth
Encompass Health
EHC
7/9
Net marginFCF marginReturn on capitalReturn on equityPiotroski F-scoreNet debt / EBITDAShare count change
Side by side
Best in the row
| Latest fiscal year | ASTH FY25 | EHC FY25 |
|---|---|---|
| Size | ||
| Market cap | $1.9B | $12.4B |
| Revenue | $3.2B | $5.9B |
| Free cash flow | $104M | $439M |
| Net income | $22.5M | $566M |
| Growth | ||
| Revenue growth | 56.4% | 10.5% |
| 5-year growth | 35.9% | 10.7% |
| Share count change | 2.9% | 0.0% |
| Profitability | ||
| Gross margin | — | — |
| Operating margin | 2.5% | — |
| Net margin | 0.7% | 9.5% |
| FCF margin | 3.3% | 7.4% |
| Return on capital | 4.2% | 15.8% |
| Return on equity | 3.0% | 25.1% |
| Balance sheet | ||
| Net debt | $609M | $2.4B |
| Net debt / EBITDA | 4.9x | 1.7x |
| Dividends and buybacks | $33.5M | $229M |
| Valuation & quality | ||
| P/E | 44.9x | 20.2x |
| Piotroski F-score | 4 | 8 |
Ten years
Revenue
Operating margin
Free cash flow
Return on capital
Each company's latest fiscal year; fiscal years end in different months. The best value in each row is highlighted where higher (or lower) is clearly better. Not investment advice.